Based on our results, an umbrella trial utilizing BCL2, MCL1/BCL2, and BFL1/MCL1 inhibitors based on BFSigs seems to be an ideal design to maximize the success of apoptosis inducing agents in AML [78]. The gene discussed is BCL2A1; the disease is acute myeloid leukemia.